ice-it presentation tct2004
DESCRIPTION
ICE-IT-1Intravascular Cooling Adjunctive to Percutaneous Coronary Intervention (Part 1)A Preliminary Review of Results TCT 2004Cindy L. Grines, MD, FACC ICE-IT-1 National PIWilliam Beaumont Hospital Royal Oak, MIIn the clinical sites who followed the protocol properly and cooled patients to a core temperature ofTRANSCRIPT
1
ICEICE--ITIT--11
A Preliminary Review of ResultsA Preliminary Review of ResultsTCT 2004TCT 2004
Cindy L. Grines, MD, FACCCindy L. Grines, MD, FACCICEICE--ITIT--1 National PI1 National PI
William Beaumont HospitalWilliam Beaumont HospitalRoyal Oak, MIRoyal Oak, MI
Intravascular Cooling Adjunctiveto Percutaneous Coronary Intervention
(Part 1)
2
BackgroundBackground
•• PreclinicalPreclinicalHypothermia reduces MI size in multiple animal models80%* relative reduction in pigs (P < 0.001)
•• ClinicalClinicalCOOL-MI Trial^
• 325 STEMI patients (157 control, 168 hypothermia)– No difference in Day 30 SPECT infarct size (1o endpoint)– Control Arm (13.8%) vs. Hypothermia Arm (14.1%), p = 0.83
• Cooling deemed safe and well-tolerated• Possible “dose-response” relationship in anterior MI subgroup
*Dae MW, et al. Am J Physiol Heart Circ Physiol 2002;282:H1584-91.
^Presented at TCT 2003 by WW O’Neill.
3
COOLCOOL--MIMI
Presented at TCT 2003 by WW O’Neill, MD
Anterior MIs Anterior MIs –– Day 30 SPECT Infarct SizeDay 30 SPECT Infarct Size
4
ICEICE--ITIT--11Study ObjectiveStudy Objective
To evaluate the safety and efficacy of mild To evaluate the safety and efficacy of mild hypothermia, as induced with the Celsius hypothermia, as induced with the Celsius ControlControl™™ System,System, when used as an adjunct towhen used as an adjunct toPCI treatment of STEMIPCI treatment of STEMI
5
Celsius ControlCelsius Control™™ SystemSystem
6
Study DesignStudy DesignAcute STEMI
Anterior or Large Inferior
(< 6 hrs of Sx onset)
Standard Care (PCI)+
HypothermiaStandard Care (PCI)
1 : 1
• Primary Endpoint: Day 30 SPECT infarct size
• Secondary Endpoints:CK-MB, NYHA Functional Class at Day 30, MACE
7
Acute MI LocationAcute MI LocationBy Baseline ECGBy Baseline ECG
NA*65 (57%)64 (56%)Large Inferior
NA*49 (43%)50 (44%)Anterior
PControlN = 114
HypothermiaN = 114
*NA: randomization algorithm stratified on the basis of infarct location
8
DemographicsDemographics
Ethnicity0.6388%86%Caucasian
12%14%Non-Caucasian
Gender0.3480%75%Men
0.9957 ± 1257 ± 13Mean ± SD (years)
0.0946 (5%)14 (12%)Patients ≥ 75 yrs
20%25%Women
108 (95%)100 (88%)Patients < 75 yrs
Age
PControlN = 114
HypothermiaN = 114
9
Baseline Clinical CharacteristicsBaseline Clinical Characteristics
0.250%3%CHF
0.502%0%Prior MI
1.0012%12%Prior thrombolytic
0.1946%54%Hypertension
0.2954%46%Smoker
1.001%1%TIA
0.371%4%Arrhythmia
0.1213%20%Diabetes
1.001%2%Stroke
PControlN = 114
HypothermiaN = 114
10
Angiographic ParametersAngiographic Parameters
5%5%Grade 2
0.9169%74%Grade 023%20%Grade 1
3%2%Grade 3
0.56N = 83N = 79LV-gram Done0.1549 ± 1247 ± 11LVEF (Mean ± SD)
20%20%3-vessel34%28%2-vessel
N = 108N = 106Collateral Flow
0.8840%45%1-vessel
4%4%4-vessel2%3%Other
N = 114N = 114No. CAD Vessels
0.510.41 ± 0.710.35 ± 0.66Mean ± SD
PControlHypothermia
11
PCI Results: TIMI FlowPCI Results: TIMI Flow
10%11%2
0%0%10.800%0%0
11%13%1
10%11%290%89%3
Final TIMI Flow
0.802.9 ± 0.32.9 ± 0.3Mean ± SD
11%12%3
0.9168%64%0Initial TIMI Flow
0.630.64 ± 1.10.69 ± 1.1Mean ± SD
PControlN = 105
HypothermiaN = 104
12
PCI Results (Cont.)PCI Results (Cont.)
0.84132 ± 90137 ± 98Sx-to-Door (min)
1.00104 (99%)104 (100%)PCI Successful*
0.9014%13%Thrombectomy
1.0099%100%Stent
0.54101 / 105 (96%)98 / 104 (94%)Ancillary Device Used
0.621%2%Embolic Protection
0.2793 ± 42103 ± 66Door-to-Balloon (min)
PControlN = 105
HypothermiaN = 104
*Success = final TIMI 2 or 3 flow, and <50% residual stenosis
13
Cooling ResultsCooling ResultsAll Patients (Mean Values)All Patients (Mean Values)
33
34
35
36
37
-2 0 2 4 6 8 10 12 14 16 18Time (hours)
Mean Manual Temp. (C)
Control Hypothermia
*
*P < 0.0001
* ** * * * *
* * *
14
AgeAge--Stratified Mortality RatesStratified Mortality Rates
•• Hypothermia Arm: 9 deathsHypothermia Arm: 9 deathsAge ≥ 75 Mortality: 36% (5 / 14)Age < 75 Mortality: 4% (4 / 100)
•• Control Arm: 5 deathsControl Arm: 5 deathsAge ≥ 75 Mortality: 33% (2 / 6)Age < 75 Mortality: 3% (3 / 108)
15
Major Adverse Cardiac EventsMajor Adverse Cardiac EventsAll PatientsAll Patients
0.2530severe CHF
0.59911MACE (any) @ 6 mo.
0.1549death (any)
0.2502re-infarction
***00stroke
0.62810MACE (any) @ 3 mo.
0.29610any MACE
0.581112MACE (any) @ 12 mo.
P
N = 114N = 114MACE thru Day 30
ControlHypothermia
16
Major Adverse Cardiac EventsMajor Adverse Cardiac EventsPatients < 75 yearsPatients < 75 years--oldold
0.2530severe CHF
0.8266MACE (any) @ 6 mo.
0.4324death (any)
0.4801re-infarction
***00stroke
1.0055MACE (any) @ 3 mo.
0.7445any MACE
0.7787MACE (any) @ 12 mo.
P
N = 108N = 100MACE thru Day 30
ControlHypothermia
17
Other Adverse EventsOther Adverse EventsNo Significant DifferencesNo Significant Differences
0.6611%13%Revascularization* (thru 30d)
0.6525%28%Infection or FUO (thru 30d)
0.8616%17%Any SAE (thru 2d)
0.7013%12%Any SAE (3d thru 30d)
0.2369%76%Any General AE (thru 2d)
PControlN = 114
HypothermiaN = 114
*PTCA or CABG of any vessel
18
Primary Efficacy EndpointPrimary Efficacy Endpoint
•• Population Evaluable for Primary EndpointPopulation Evaluable for Primary Endpoint217 pts (108H / 109C)Includes 13 deaths (9H / 4C)
• Imputed “worst outcome” by AMI location• 58% (of LV) imputed for anterior MI deaths• 35% (of LV) imputed for inferior MI deaths
Excludes 11 pts lost to follow-up (6H / 5C)
•• Patients with Actual (Measured) SPECTPatients with Actual (Measured) SPECT204 pts (99H / 105C)No imputed values
Day 30 SPECT Infarct SizeDay 30 SPECT Infarct Size
19
Primary Efficacy EndpointPrimary Efficacy EndpointMean SPECT Infarct Size (% of LV)Mean SPECT Infarct Size (% of LV)
13.5
10.2
14.213.2
0
5
10
15
20
All EvaluablePatients
Measured*SPECT
% HypothermiaControl
N = 108 N = 109 N = 99 N = 105
*No imputed values
23% Relative Reduction
P = 0.14P = 0.77
20
Primary Efficacy EndpointPrimary Efficacy EndpointMean SPECT Infarct Size^ (% of LV): Mean SPECT Infarct Size^ (% of LV): By MI LocationBy MI Location
^No imputed values
15.3
6.5
20.9
7.4
0
5
10
15
20
25
Anterior Inferior
% HypothermiaControl
N = 41 N = 45
27% Relative Reduction
P = 0.15
N = 58 N = 60
12% Relative Reduction
P = 0.60
21
SiteSite--Dependent ResultsDependent Results
*Negative value represents an increase in infarct size (Hyp vs. Ctl)
0.69911%20 / 31Good (15 sites)
0.14223%99 / 105TOTAL (23 sites)
0.104– 134%21 / 16Fair (2 sites)
0.01744%58 / 58Excellent (6 sites)
PRelative Reduction*
N(Hyp / Ctl)
Protocol Compliance
Relative Reductions in Mean SPECT Infarct SizeRelative Reductions in Mean SPECT Infarct Size
22
22.7
16.3
12.9
17.6
0
5
10
15
20
25
Hypothermia Control
%Control (N = 38)All Hypo (N = 36)Tpci <35 (N = 10)Tpci >35 (N = 26)
Temp at PCI Temp at PCI –– All SitesAll SitesAnterior MIsAnterior MIs –– Mean SPECT Infarct Size^ (% of LV)Mean SPECT Infarct Size^ (% of LV)
P = 0.13 (28% reduction)
^No imputed values
P = 0.09 (43% reduction)
23
7.4
6.5
4.5
7.7
0
2
4
6
8
10
Hypothermia Control
%Control (N = 59)All Hypo (N = 50)Tpci <35 (N = 19)Tpci >35 (N = 31)
Temp at PCI Temp at PCI –– All SitesAll SitesInferior MIsInferior MIs –– Mean SPECT Infarct Size^ (% of LV)Mean SPECT Infarct Size^ (% of LV)
P = 0.60 (12% reduction)
^No imputed values
P = 0.16 (39% reduction)
24
5.9
48
4.8
54
0
10
20
30
40
50
60
Admission Peak
CK
-MB
HypothermiaControl
Secondary EndpointSecondary EndpointNormalized Peak CKNormalized Peak CK--MB (Value / ULN)MB (Value / ULN)
N = 70 N = 68 N = 88 N = 87
P = 0.079
11% Relative Reduction
P = 0.096
25
ConclusionsConclusions•• ICEICE--ITIT--11
Baseline population imbalance• Hypothermia arm had more elderly patients ≥ 75yrs. • Age-adjusted mortality and MACE rates virtually identical
Analysis of SPECT data (without imputed values)• Suggests that a 20 – 40% relative reduction of infarct size is possible• Cooling “dose response” observed (≤ 35°C at time of reperfusion)
– Observed in both anterior and inferior MIs.
•• ICEICE--ITIT--22Initial planning underway